Ebselen

Ebselen

SCHEMBL33829

O=c1c2ccccc2[se]n1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 5/20 1.00
KDM4E B2RXH2 1/20 1.00
MEN1 O00255 1/20 1.00
QSOX1 O00391 1/20 1.00
RGS12 O14924 1/20 1.00
PMM2 O15305 1/20 1.00
PLIN1 O60240 1/20 1.00
GMNN O75496 1/20 1.00
BBOX1 O75936 1/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 1/20 1.00
TP53 P04637 1/20 1.00
CYBB P04839 1/20 1.00
BCHE P06276 1/20 1.00
GLA P06280 1/20 1.00
POLB P06746 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
MAPT P10636 1/20 1.00
G6PD P11413 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ebselen SCHEMBL29370082 1.00 METAP2 (1.00) METAP2KDM4EMEN1QSOX1RGS12
Ebselen SCHEMBL4406056 1.00 METAP2 (1.00) METAP2KDM4EMEN1QSOX1RGS12
Ebselen SCHEMBL19064566 0.98 METAP2 (0.96) METAP2KDM4EMEN1QSOX1RGS12
Ebselen SCHEMBL20678555 0.98 METAP2 (0.96) METAP2KDM4EMEN1QSOX1RGS12
Ebselen SCHEMBL20477111 0.98 METAP2 (0.96) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL193047 0.89 METAP2 (0.79) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL28783439 0.87 METAP2 (0.77) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL10501092 0.85 METAP2 (1.00) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL10502294 0.85 METAP2 (1.00) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL1354655 0.85 METAP2 (0.74) METAP2KDM4EMEN1QSOX1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 14182 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228644-B1 N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 NANTCELL INC (US) 2026-05-27 EP claimed
CN-122080099-A Amphiphilic nicotinamide adenine dinucleotide conjugate, nano micelle and application thereof 2026-05-26 CN claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-4744663-A2 SKIN COMPOSITION Eaderm Co., Ltd. (JP) 2026-05-20 EP claimed
US-12628816-B2 Storage solution including an aqueous culture medium and methods of preservation of live allografts RESTORATION BIOLOGICS LLC (US) 2026-05-19 US claimed
US-20260125650-A1 METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES TRAILHEAD BIOSYSTEMS INC (US) 2026-05-07 US claimed
US-20260115231-A1 TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS SPINALCYTE LLC (US) 2026-04-30 US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
EP-4114975-B1 FASCIN-2 (FSCN2) VARIANT AND USE THEREOF REGENERON PHARMA (US) 2026-04-29 EP claimed
EP-4725496-A2 N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 NantCell, Inc. (US) 2026-04-15 EP claimed
EP-0354412-A2 Process for the preparation of highly pure ebselene A. Nattermann & Cie. GmbH (DE) 1990-02-14 EP claimed
EP-0347927-A2 Use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen) in the preparation of medicaments for the treatment of malaria A. Nattermann & Cie. GmbH (DE) 1989-12-27 EP claimed
EP-0296389-A1 Pharmaceutical compositions with micronised Ebselen crystals A. Nattermann & Cie. GmbH (DE) 1988-12-28 EP claimed
US-4784994-A Process for the treatment of inflammatory and allergic diseases A. NATTERMANN & CIE GMBH (DE) 1988-11-15 US claimed
US-4757063-A Administering 2-phenyl-1,2-benzisoselenazol-3(2H)-one A. NATTERMANN & CIE. GMBH (DE) 1988-07-12 US claimed
EP-0249736-A2 Ointment for the treatment of skin diseases A. Nattermann & Cie. GmbH (DE) 1987-12-23 EP claimed
EP-0249735-A2 Pharmaceutical preparations comprising as active agent 2-phenyl-1.2-benzisoselenazol-3(2H)-one, for the treatment of diseases caused by oxidative stress A. Nattermann & Cie. GmbH (DE) 1987-12-23 EP claimed
EP-0044971-B1 2-PHENYL-1.2-BENZISOSELENAZOL-3(2H)-ONE CONTAINING PHARMACEUTICAL PREPARATIONS AND THEIR USE A. Nattermann & Cie. GmbH (DE) 1983-07-20 EP claimed
US-4352799-A ANTISCLEROTIC, ANTIINFLAMMATORY A. NATTERMANN & CIE GMBH (DE) 1982-10-05 US claimed
EP-0044971-A1 2-Phenyl-1.2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and their use A. Nattermann & Cie. GmbH (DE) 1982-02-03 EP claimed